サンプル依頼リスト カート
  • English
  • Korean
表紙：RSウイルス治療薬の世界市場-2023年～2030年
市場調査レポート
商品コード
1297785

RSウイルス治療薬の世界市場-2023年～2030年

Global Respiratory Syncytial Virus (RSV) Therapeutics Market - 2023-2030
出版日: | 発行: DataM Intelligence | ページ情報: 英文 195 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
RSウイルス治療薬の世界市場-2023年～2030年
出版日: 2023年06月15日
発行: DataM Intelligence
ページ情報: 英文 195 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

市場概要

RSウイルス治療薬の世界市場は、2022年に12億米ドルに達し、2030年には最大24億米ドルに達することで有利な成長を示すと予測されています。世界のRSウイルス治療薬市場は、予測期間中（2023～2030年）に10.2％のCAGRを示すと予測されています。病院入院の増加や新薬の臨床試験の増加が、RSウイルス治療薬市場動向の需要を押し上げています。

RSウイルスは、一般的なウイルス感染症であり、主に新生児や幼児の呼吸器系に感染します。RSウイルスはまた、高齢者や免疫系が低下した人々にも深刻な呼吸器感染症を引き起こす可能性があります。RSウイルスは乳幼児が入院する最も一般的な原因です。効果的な治療法は感染の重症度を軽減し、入院の必要性を減らすため、ヘルスケアシステムへの負担を軽減することができます。

市場力学

主要企業による臨床試験の増加が市場成長を牽引する見込み

主要企業による臨床試験の増加が市場成長を促進すると予測されます。例えば、2023年5月8日、Ascletis Pharma Inc.によると、中国国家医薬品監督管理局（「NMPA」）は、RSウイルス感染症を治療するためのASC10の第IIa相臨床試験を承認しました。

軽症または中等症のRSV感染症患者を対象に、ASC10錠の抗ウイルス効果、安全性、忍容性、薬物動態を評価する無作為化二重盲検プラセボ対照第IIa相試験において、入手可能な結果に基づき、ASC10 800 mg 1日2回投与が選択されました。臨床試験により市場成長も期待できます。

有望な結果を示す製品の強力なパイプラインが市場成長を促進

RSVとの闘いで製薬会社が研究している主要な戦術の1つは、新生児にモノクローナル抗体を使用して受動免疫を引き起こすことです。このパイプラインは、シナジスや妊娠中の母親へのワクチン接種という代替技術を凌駕し、新生児に受動免疫をもたらします。新しいメカニズム、安価なコスト、1回の注射で全シーズンを予防できること、即座に病気を予防できることなどが、市場の成長を後押しすると期待されています。

例えば、2022年04月07日に提案された買収は、呼吸器合胞体ウイルス（RSV）感染症の治療による患者の転帰の改善とワクチン接種による病気の予防を支援する補完的な戦略を提供することで、ファイザーの感染症研究開発能力を拡大します。ファイザーのユニークな抗感染症薬ポートフォリオは拡大され、同社の研究開発、製造、商品化の専門知識は、RSV治療に対する大きなアンメット需要を満たすために活用されます。その結果、著名メーカーがRSV治療用の新薬に注力することで、市場の拡大が促進されるであろう。

高い疾病管理コストが市場成長の妨げになります

RSウイルスの管理コストは高く、市場成長の妨げになると予想されます。NLMによると、メディケイドは新生児RSVHの61%をカバーしています。メディケイドは新生児RSVH費用の51％をカバーし、入院1回当たりの支払額は民間保険より32％少なかっています。新生児のRSウイルス治療費は年間7億960万米ドルで、出産1件あたり187ドル、公費分娩1件あたり227ドルです。この要因は、世界のRSV市場の進展をさらに妨げる可能性があります。

COVID-19の影響分析

RSウイルスに対するCOVID-19の影響は複雑です。COVID-19パンデミックの間、RSVの疫学と臨床パターンは劇的に変化しました。マスクの使用、社会的距離の取り方、手指衛生の改善など、COVID-19感染を減らすことを目的とした非薬物的アプローチにより、RSウイルスの症例はかなり減少しました。

RSV感染に対するCOVID-19の影響は、RSV感染の再発と影響を抑えるために、継続的なサーベイランス、準備、効率的な予防・治療戦略の開発の重要性を浮き彫りにしました。

ロシア・ウクライナ紛争の影響分析

ロシア・ウクライナ紛争は、同地域の主要市場プレイヤーの数が少ないことから、世界のRSウイルス治療薬市場に与える影響は中程度と推定されます。しかし、原材料の輸出入の影響は、予測期間中、世界のRSウイルス治療薬市場の成長にほとんど影響を与えないと予測されます。

人工知能の影響分析

人工知能は、世界のRSウイルス治療薬市場の成長にプラスの影響を与えると予想されます。AIは、特定のウイルス標的に結合する可能性のある分子を同定するために、大規模な化学ライブラリーの仮想スクリーニングに使用することができます。計算モデルやアルゴリズムを使用することで、研究者は数千から数百万の化合物の結合親和性を予測することができ、さらなる試験のための有望な候補を特定することができます。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 主要企業別臨床試験の増加
      • 有望な結果を示す製品の強力なパイプライン
    • 抑制要因
      • 疾病管理コストの高さ
    • 機会
      • RSウイルス感染と闘い、予防するための効果的な治療法の開発
    • 影響分析

第5章 産業分析

  • ポーターの5フォース分析
  • サプライチェーン分析
  • アンメットニーズ
  • 規制分析

第6章 COVID-19分析

第7章 ロシア・ウクライナ戦争分析

第8章 人工知能の影響分析

第9章 薬剤タイプ別

  • リバビリン
  • ニルセビマブ
  • ビラゾール
  • パリビズマブ
  • リバタブ
  • その他

第10章 剤形別

  • 経口剤
  • 注射剤
  • 吸入剤
  • その他

第11章 治療タイプ別

  • 免疫予防
  • 支持療法
  • 抗ウイルス薬

第12章 流通チャネル別

  • 病院薬局
  • 小売薬局
  • オンライン薬局

第13章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋地域
  • 中東・アフリカ

第14章 競合情勢

  • 競合シナリオ
  • 市場シェア分析
  • M&A分析

第15章 企業プロファイル

  • Sanofi
    • 企業概要
    • 製品ポートフォリオと概要
    • 財務概要
    • 主な発展
  • GSK plc
  • Pfizer
  • AstraZeneca
  • AbbVie
  • Bausch Health Companies
  • Bavarian Nordic
  • Merck & Co
  • Moderna, Inc.
  • mAbxience.

第16章 付録

目次
Product Code: BT6460

Market Overview

The Global Respiratory Syncytial Virus (RSV) Therapeutics Market reached US$ 1.2 billion in 2022 and is projected to witness lucrative growth by reaching up to US$ 2.4 billion by 2030. The global Respiratory Syncytial Virus (RSV) therapeutics market is expected to exhibit a CAGR of 10.2% during the forecast period (2023-2030). The increasing hospital admissions and the growing clinical trialsfor novel drugs are driving up demand for respiratory syncytial virus therapeutics market trends.

Respiratory Syncytial Virus (RSV) is a common viral infection that mostly affects newborns and young children's respiratory systems. RSV can also cause serious respiratory infection in elderly people and those with compromised immune systems. RSV is the most common cause of hospitalisation among babies and young children. Effective therapies may lessen the severity of the infection, reduce the need for hospitalization, and so reduce the pressure on healthcare systems.

Market Dynamics

Rise in the Clinical Trials by the Key Players is expected to Drive the Market Growth

The increase in clinical trials by key companies is projected to fuel market growth. For instance, May 8, 2023, The China National Medical Products Administration ("NMPA") has approved a Phase IIa clinical trial for ASC10 to treat respiratory syncytial virus (RSV) infection, according to Ascletis Pharma Inc.

Based on the available results, a dose of 800 mg ASC10 twice daily was chosen for a randomised, double-blind, placebo-controlled Phase IIa research to assess the antiviral efficacy, safety, tolerability, and pharmacokinetics of ASC10 tablets in patients with mild or moderate RSV infection. Clinical trials will also increase market growth.

Strong Pipeline of Products Showing Promising Results to Propel market growth

One of the primary tactics being investigated by pharmaceutical companies in their fight against RSV is the use of monoclonal antibodies in newborns to cause passive immunisation. The pipeline items outperform Synagis and the alternative technique of vaccination pregnant moms to deliver passive immunisation to infants. Novel mechanisms, cheaper costs, and protection for the full season with a single injection, as well as instant disease prevention, are expected to boost market growth.

For instance, on April 07, 2022, the proposed acquisition expands Pfizer's infectious disease research and development capabilities by providing a complementary strategy to help improve patient outcomes through treatment for respiratory syncytial virus (RSV) infections and prevent sickness through vaccination. Pfizer's unique anti-infective portfolio is being expanded, and the company's R&D, manufacturing, and commercialization expertise is being used to meet a substantial unmet demand for RSV treatments. As a result, prominent manufacturers' focus on novel medications to treat RSV will fuel market expansion.

High Cost of Disease Management will hamper the market growth.

The cost of managing RSV is high, which is expected to limit market growth. According to the NLM, Medicaid covered 61% of newborn RSVHs. Medicaid covered 51% of baby RSVH costs, paying 32% less per hospitalisation than commercial insurance. RSV therapy for infants costs $709.6 million per year, or $187 per total birth and $227 every publicly financed delivery. This factor may further hinder the global RSV market's progress.

COVID-19 Impact Analysis

The effect of COVID-19 on Respiratory Syncytial Virus (RSV) has been complicated. During the COVID-19 pandemic, RSV epidemiology and clinical patterns changed dramatically. Non-pharmaceutical approaches aimed at reducing COVID-19 transmission, including as mask use, social distancing, and improved hand hygiene, resulted in a considerable decrease in RSV cases.

The influence of COVID-19 on RSV infection has highlighted the importance of ongoing surveillance, readiness, and the development of efficient preventative and therapeutic strategies to limit the recurrence and impact of RSV infections.

Russia-Ukraine War Impact Analysis

The Russia-Ukraine conflict is estimated to have a moderate impact on the global respiratory syncytial virus therapeutics market, owing to the low number of key market players in this region. However, the impact of the import and export of raw materials is expected to have little influence over the global respiratory syncytial virus therapeutics market growth over the forecast period.

Artificial Intelligence Impact Analysis

Artificial intelligence is anticipated to impact the growth of global respiratory syncytial virus therapeutics market positively. AI can be used for virtual screening of large chemical libraries to identify molecules with the potential to bind to specific viral targets. By using computational models and algorithms, researchers can predict the binding affinity of thousands or millions of compounds, allowing them to identify promising candidates for further testing

Segment Analysis

The global respiratory syncytial virus therapeutics market is segmented based on drug type, dosage form, treatment type, distribution channel and region.

Hospital Pharmacy from Distribution Channel Segment Accounts for 41.3% of Market Share

Because RSV infection is common in neonates and infants, therapy for these populations must be closely monitored around the clock, resulting in a high hospitalisation rate in cases of RSV infection. RSV is more common in the winter and spring months in the United States. RSV is a virus that can be treated on an outpatient basis in the majority of children and newborns. However, between 0.5 to 2% of children and newborns with RSV may require hospitalisation.

For instance, according to CDC, RSV causes approximately 2.4 million outpatient (non-hospitalization) visits among children under the age of five in the United States each year. 60,000-90,000 hospitalisations among children under the age of five. In addition, 50,000-150,000 hospitalisations among aged 65 and older. As a result, those figures will drive the growth of the hospital pharmacy segment.

Geographical Analysis

Asia Pacific Accounted for Approximately 22.4% of the Market Share

Due to the high population density and rapidly increasing frequency of infectious disorders, the Asia Pacific respiratory syncytial virus diagnostics market is predicted to develop the fastest over the forecast period. Strong need for automated healthcare testing for accurate and faster disease diagnosis is projected to drive regional market expansion.

Due to rising healthcare systems and an increasing number of government programmes, China, India, Japan, and Malaysia are likely to be the region's fastest-growing markets. Furthermore, the expanding newborn population is likely to drive market growth.

For instance, according to TheWorldCounts, Every year, over 140 million infants are born around the world. Every second, more than four babies are born. Every year, Asia accounts for more than half of global births, with 25 million births in India and 16 million births in China alone. These indicators indicate that Asia Pacific will dominate the market.

Competitive Landscape

The major global players in the market include: Sanofi, GSK plc, Pfizer, AstraZeneca, AbbVie, Bausch Health Companies, Bavarian Nordic, Merck & Co, Moderna, Inc., and mAbxience, among others.

Why Purchase the Report?

  • To visualize the global respiratory syncytial virus therapeutics market segmentation based on infection type, drug type, end user and region,as well as understandkey commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of respiratory syncytial virus therapeutics market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as Excel consisting of key products of all the major players.

The global respiratory syncytial virus therapeutics market report would provide approximately 53 tables, 54 figures and 195 pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Drug Type
  • 3.2. Snippet by Dosage Form
  • 3.3. Snippet by Treatment Type
  • 3.4. Snippet by Distribution Channel
  • 3.5. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rise in the Clinical Trails by the Key Players
      • 4.1.1.2. Strong Pipeline of Products Showing Promising Results
    • 4.1.2. Restraints
      • 4.1.2.1. High Cost of Disease Management
    • 4.1.3. Opportunity
      • 4.1.3.1. Development of effective treatments to combat and prevent RSV infections
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's 5 Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Unmet Needs
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario before COVID-19
    • 6.1.2. Scenario during COVID-19
    • 6.1.3. Scenario Post COVID-19
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturers' Strategic Initiatives
  • 6.6. Conclusion

7. Russia-Ukraine War Analysis

8. Artificial Intelligence Impact Analysis

9. By Drug Type

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 9.1.2. Market Attractiveness Index, By Drug Type
  • 9.2. Ribavirin
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Nirsevimab
  • 9.4. Virazole
  • 9.5. Palivizumab
  • 9.6. Riba Tab
  • 9.7. Others

10. By Dosage Form

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage Form
    • 10.1.2. Market Attractiveness Index, By Dosage Form
  • 10.2. Oral
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.3. Injectable
  • 10.4. Inhaler
  • 10.5. Others

11. By Treatment Type

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 11.1.2. Market Attractiveness Index, By Treatment Type
  • 11.2. Immune prophylaxis
    • 11.2.1. Introduction
    • 11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 11.3. Supportive care
  • 11.4. Antiviral Medications

12. By Distribution Channel

  • 12.1. Introduction
    • 12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 12.1.2. Market Attractiveness Index, By Distribution Channel
  • 12.2. Hospital Pharmacy
    • 12.2.1. Introduction
    • 12.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 12.3. Retail Pharmacy
  • 12.4. Online Pharmacy

13. By Region

  • 13.1. Introduction
    • 13.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 13.1.2. Market Attractiveness Index, By Region
  • 13.2. North America
    • 13.2.1. Introduction
    • 13.2.2. Key Region-Specific Dynamics
    • 13.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 13.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage Form
    • 13.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 13.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 13.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 13.2.7.1. The U.S.
      • 13.2.7.2. Canada
      • 13.2.7.3. Mexico
  • 13.3. Europe
    • 13.3.1. Introduction
    • 13.3.2. Key Region-Specific Dynamics
    • 13.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 13.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage Form
    • 13.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 13.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 13.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 13.3.7.1. Germany
      • 13.3.7.2. The U.K.
      • 13.3.7.3. France
      • 13.3.7.4. Italy
      • 13.3.7.5. Spain
      • 13.3.7.6. Rest of Europe
  • 13.4. South America
    • 13.4.1. Introduction
    • 13.4.2. Key Region-Specific Dynamics
    • 13.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 13.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage Form
    • 13.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 13.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 13.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 13.4.7.1. Brazil
      • 13.4.7.2. Argentina
      • 13.4.7.3. Rest of South America
  • 13.5. Asia-Pacific
    • 13.5.1. Introduction
    • 13.5.2. Key Region-Specific Dynamics
    • 13.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 13.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage Form
    • 13.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 13.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 13.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 13.5.7.1. China
      • 13.5.7.2. India
      • 13.5.7.3. Japan
      • 13.5.7.4. Australia
      • 13.5.7.5. Rest of Asia-Pacific
  • 13.6. Middle East and Africa
    • 13.6.1. Introduction
    • 13.6.2. Key Region-Specific Dynamics
    • 13.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 13.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage Form
    • 13.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 13.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

14. Competitive Landscape

  • 14.1. Competitive Scenario
  • 14.2. Market Share Analysis
  • 14.3. Mergers and Acquisitions Analysis

15. Company Profiles

  • 15.1. Sanofi
    • 15.1.1. Company Overview
    • 15.1.2. Type Portfolio and Description
    • 15.1.3. Financial Overview
    • 15.1.4. Key Developments
  • 15.2. GSK plc
  • 15.3. Pfizer
  • 15.4. AstraZeneca
  • 15.5. AbbVie
  • 15.6. Bausch Health Companies
  • 15.7. Bavarian Nordic
  • 15.8. Merck & Co
  • 15.9. Moderna, Inc.
  • 15.10. mAbxience.

LIST NOT EXHAUSTIVE

16. Appendix

  • 16.1. About Us and Services
  • 16.2. Contact Us